MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells [0.03%]
一种新的选择性细胞毒化合物MICONIDINE乙酸盐具有协同作用潜能，可诱导白血病细胞周期阻滞和凋亡
Mariana Franzoni Maioral,Natália Marceli Stefanes,Álisson Bigolin et al.
Mariana Franzoni Maioral et al.
Plants are important sources of biologically active compounds and they provide unlimited opportunities for the discovery and development of new drug leads, including new chemotherapeutics. Miconidin acetate (MA) is a hydroquinone derivative...
Cyclodextrin polymers decorated with RGD peptide as delivery systems for targeted anti-cancer chemotherapy [0.03%]
RGD肽修饰的环糊精聚合物作为靶向抗肿瘤化疗的递送系统
Maurizio Viale,Rita Tosto,Valentina Giglio et al.
Maurizio Viale et al.
Polymeric cyclodextrin-based nanoparticles are currently undergoing clinical trials as nanotherapeutics. Using a non-covalent approach, we decorated two cross-linked cyclodextrin polymers of different molecular weights with an RGD peptide d...
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer [0.03%]
F14512（一种聚胺传递型拓扑异构酶II抑制剂）治疗铂耐药或难治性卵巢癌I期剂量递增研究
Alexandra Leary,Christophe Le Tourneau,Andrea Varga et al.
Alexandra Leary et al.
Purpose To determine the maximum tolerated dose (MTD) of F14512, a topoisomerase II inhibitor designed to target cancer cells through the polyamine transport system, (three-hour daily infusion given for 3 consecutive days every 3 weeks) in ...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):693-701. DOI:10.1007/s10637-018-0688-4 2019
The availability of drug by liposomal drug delivery : Individual kinetics and tissue distribution of encapsulated and released drug in mice after administration of PEGylated liposomal prednisolone phosphate [0.03%]
脂质体给药中的药物可及性：PEG化脂质体给药后载药和释放的泼尼松磷酸酯在小鼠中的群体动力学和组织分布
Evelien A W Smits,José A Soetekouw,Ebel H E Pieters et al.
Evelien A W Smits et al.
Lately, the usefulness of liposomal drug delivery systems has been debated. To better understand the underlying pharmacokinetics of the targeted drug delivery by liposomes, individual encapsulated and non-encapsulated drug concentrations in...
Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in human adenocarcinoma cells [0.03%]
PI3K/Akt致癌信号途径调控剂影响人腺癌细胞中mTOR复合物2
Blair P Curless,Nne E Uko,Diane F Matesic
Blair P Curless
Chaetoglobosin K (ChK) is a natural product that has been shown to promote F-actin capping, inhibit growth, arrest cell cycle G2 phase, and induce apoptosis. ChK also has been shown to downregulate two important kinases involved in oncogeni...
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis [0.03%]
兰重组兰瑞肽治疗转移性胃肠胰神经内分泌肿瘤的疗效和安全性：一项回顾性分析
Junho Kang,Changhoon Yoo,Hee-Sang Hwang et al.
Junho Kang et al.
Lanreotide autogel is a long-acting somatostatin analogue with proven efficacy and safety in patients with well-differentiated (WD) gastroenteropancreatic-neuroendocrine tumors (GEP-NETs) in a prior randomized phase III trial (CLARINET). Ho...
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma [0.03%]
雷莫芦单抗失败后的肝癌患者接受索拉非尼治疗的疗效和安全性的真实世界研究
Changhoon Yoo,Joong-Won Park,Yoon Jun Kim et al.
Changhoon Yoo et al.
Background The pivotal RESORCE trial showed that regorafenib was effective as second-line therapy for patients with advanced HCC who progressed on first-line sorafenib. Real-world data are needed to assess clinical outcomes and adverse even...
Multicenter Study
Investigational new drugs. 2019 Jun;37(3):567-572. DOI:10.1007/s10637-018-0707-5 2019
A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer [0.03%]
一种新型靶向程序性死亡受体1和酪氨酸蛋白激酶Met的四价双特异性抗体治疗胃癌
Weihua Hou,Qingyun Yuan,Xingxing Yuan et al.
Weihua Hou et al.
Background Redirecting T cells to tumor cells using bispecific antibodies (BsAbs) is emerging as a potent cancer therapy. The main concept of this strategy is to cross-link tumor cells and T cells by simultaneously binding to cell surface t...
First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors [0.03%]
TAS-114联合S-1治疗晚期实体瘤的首次人体Ⅰ期临床研究
Toshihiko Doi,Kiyotaka Yoh,Kohei Shitara et al.
Toshihiko Doi et al.
Background This first-in-human phase 1 study assessed the safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 to determine its maximum tolerated dose (MTD) and recommended dose (RD). Methods In this dose-esca...
Clinical Trial
Investigational new drugs. 2019 Jun;37(3):507-518. DOI:10.1007/s10637-018-0697-3 2019
The role of oxidative stress in 63 T-induced cytotoxicity against human lung cancer and normal lung fibroblast cell lines [0.03%]
氧化应激在63T诱导的人肺癌和正常肺成纤维细胞系的细胞毒作用中的作用
Malgorzata Kucinska,Helena Mieszczak,Hanna Piotrowska-Kempisty et al.
Malgorzata Kucinska et al.
It has been shown previously that molecules built on benzanilide and thiobenzanilide scaffolds possess differential biological properties including selective anticancer activity. In our previous study, we examined the cytotoxic activity and...